BeiGene’s Blincyto (blinatumomab) Receives the NMPA’s Approval for Pediatric Patients with Relapsed or Refractory B-Cell Precursor ALL
- NMPA has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with r/r CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)
- This approval is based on ex-China research data and Chinese adult data. The full approval in this indication will be based on the results of a post-marketing study in China
- This approval marked the second approval for the therapy in China. Blincyto is a BiTE (bispecific T-cell engager) immuno-oncology therapy that targets CD19 surface antigens on B cells
Ref: BeiGene | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].